https://www.selleckchem.com/products/ms-275.html
Due to the biological heterogeneity, 60%-70% of patients with major depressive disorder (MDD) do not respond to or achieve remission from first-line antidepressants. Predicting neuroimaging biomarkers for early antidepressant treatment could guide initial antidepressant therapy. To assess for neuroimaging biomarkers for antidepressant selection in early antidepressant treatment. Prospective. A total of 85 MDD patients from the major site and 33 MDD patients from an out-of-sample test site. A 3.0 T, T1-weighted imaging using a magnetizati
Giống
Bình luận
Đăng lại
